Afatinib versus methotrexate in older patients with second-line recurrent and/or metastatic head and neck squamous cell carcinoma: subgroup analysis of the LUX-Head & Neck 1 trial(†)

BACKGROUND: In the phase III LUX-Head & Neck 1 (LHN1) trial, afatinib significantly improved progression-free survival (PFS) versus methotrexate in recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) patients progressing on/after platinum-based therapy. This report ev...

Descripción completa

Detalles Bibliográficos
Autores principales: Clement, P. M., Gauler, T., Machiels, J. P., Haddad, R. I., Fayette, J., Licitra, L. F., Tahara, M., Cohen, E. E. W., Cupissol, D., Grau, J. J., Guigay, J., Caponigro, F., de Castro, G., de Souza Viana, L., Keilholz, U., del Campo, J. M., Cong, X. J., Ehrnrooth, E., Vermorken, J. B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2016
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4959921/
https://www.ncbi.nlm.nih.gov/pubmed/27084954
http://dx.doi.org/10.1093/annonc/mdw151

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4959921/
https://www.ncbi.nlm.nih.gov/pubmed/27084954
http://dx.doi.org/10.1093/annonc/mdw151

Ejemplares similares